• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2001
      • 7.1.1.3 2002
      • 7.1.1.4 2003
      • 7.1.1.5 2004
      • 7.1.1.6 2005
      • 7.1.1.7 2006
      • 7.1.1.8 2007
      • 7.1.1.9 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Merz bets on growth - Hans-Jörg Bergler takes over leadership of the newly created Corporate Development / Mergers & Acquisitions department

Frankfurt am Main, 04.06.2007

To take affect immediately, Hans-Jörg Bergler (38) will be responsible for the newly created area of Corporate Development / Mergers & Acquisitions at Merz GmbH & Co. KGaA. This function will serve to accelerate the Merz Group's external growth.

In order to strengthen external growth alongside the already well-developing organizational growth, Merz has created the new area of Corporate Development / Mergers & Acquisitions. Under the leadership of Hans-Jörg Bergler, the function will investigate strategic opportunities for expansion in regards to the acquisition of companies, products, or in-licensing projects.

Armin von Buttlar, CFO of the Merz Group, states: "Merz has set some ambitious goals for itself. We want to double our concern's overall revenue from the current 500 million Euros by 2015. We're glad we've found a highly qualified figure for the expansion of our external growth in Bergler."

Bergler can look back on long-time experience in Corporate Development and Mergers & Acquisitions within the pharma industry, including at the companies Altana Pharma and Boehringer-Ingelheim, amongst others.

About Merz

Merz specializes in drugs for the treatment of neurological and psychiatric illnesses and is a leader in the field of Alzheimer's research. Merz developed Memantine, the world's first drug for the treatment of moderate to severe stages of Alzheimer's disease. Among drugs to combat Alzheimer's, Memantine is the second-largest in the world. Another area of competence at Merz is clinical and cosmetic dermatology.
Along with the pharmaceuticals market, Merz is active in the healthcare sector outside of pharmacies as well. With its tetesept® and Merz Spezial® brands, in German-speaking countries Merz is a leading provider of products for self-medication, dietary supplements, beauty and wellness.A Merz subsidiary, Senator GmbH & Co. KGaA, is one of the leading manufacturers of high-quality promotional writing instruments worldwide. The Merz Group employs 1,900 employees worldwide.

The company achieved revenues of € 475 million in the 2005/06 fiscal year.

Download:

Hans-Jörg Bergler takes over leadership of the newly created Corporate Development / Mergers & Acquisitions department

Photographic material available on request.

Contact:

Merz GmbH & Co. KGaA
Ute Weinhold
Corporate Communications
Eckenheimer Landstraße 100
60318 Frankfurt
GERMANY
Tel.: + 49 (0)69 / 15 03 - 889
Fax: + 49 (0)69 / 15 03 - 581
E-Mail: ute.weinhold@merz.de

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s